Novo Nordisk has signed a deal with AI-driven protein design company Gensaic to develop tissue-targeted therapies for ...

Privately-held Cambridge, USA-based biotech Gensaic announced a potentially lucrative license and discovery collaboration ...

Novo is paying Gensaic up to $354 million per target in upfront fees and development and commercial milestones, plus tiered ...

Gensaic partnership with Novo Nordisk, worth up to $354M, aims to develop next-generation precision therapies using novel protein design technology.

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Gensaic, Inc. (Gensaic), a biotechnology company that combines AI-powered protein design with biological insights to discover ligands for tissue-selective ...

A national survey conducted by MedStar Health to gauge the public's knowledge of screening guidelines for colorectal cancer, ...

RevSpring, the leading provider of healthcare engagement and payment solutions, today announced Let's Talktm?an always-available virtual agent that seamlessly handles inbound calls from ...

Credit: Victor Golmer via Getty Images. Novo Nordisk has signed a deal with AI-driven protein design company Gensaic to develop tissue-targeted therapies for cardiometabolic diseases. The ...

Leading pharmaceutical associations in Russia have called on the government to postpone the introduction of new procurement ...